跳至主要内容
临床试验/NCT02554708
NCT02554708已完成不适用

pToWin pCONus Treatment of Wide Neck Intracranial Aneurysms

Phenox GmbH10 个研究点 分布在 5 个国家目标入组 116 人开始时间: 2015年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Phenox GmbH
入组人数
116
试验地点
10
主要终点
Effectiveness Aneurysm occlusion (complete or neck remnant)

研究概览

简要总结

To assess safety and efficacy of pCONus for the treatment of wide neck bifurcation aneurysms.

详细描述

Title: pCONus Treatment of Wide Neck Intracranial Aneurysms

Acronym: pToWin

Device: pCONus Bifurcation Aneurysm Implant

Study design: Prospective, multicenter, single-arm clinical investigation

Purpose: To assess safety and efficacy of pCONus for the treatment of wide neck bifurcation aneurysms

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aneurysm status:
  • Unruptured aneurysm or
  • Ruptured aneurysm with a Hunt and Hess grade of I - III.
  • Age ≥18 and ≤ 80 years.
  • The patient or legal representative provides written informed consent.
  • The patient shows general compliance to follow the medical regimen and to attend follow-up examinations.
  • The target aneurysm is located at one of the following cerebral vessel bifurcations: ICA terminus, AcomA, MCA or BA.
  • Bifurcation wide neck aneurysm.
  • The dome height should allow for safe deployment of the device crown. The fundus of the aneurysm should offer enough space for the crown of the pCONus to deploy.

排除标准

  • Vessel tortuosity precluding safe access and device deployment.
  • Stenosis within the vascular access or target vessel ≥ 50 %.
  • The target aneurysm has been previously treated with a stent or an intraaneurysmal implant beside coils.
  • The treatment plan for the target aneurysm includes the use of additional intra- and/or extraaneurysmal temporary or permanent implants other than coils.
  • More than one intracerebral aneurysm requires the treatment within the following 6 months.
  • Imaging evidence of an arteriovenous cerebrovascular malformation or a dural fistula.
  • Any physical, medical or psychiatric condition of the patient interfering with the adherence of the requirements and follow-up regimen of the study.
  • Any neurological disorder with progressive neurological symptoms, except attributable to a compressive effect of the target aneurysm.
  • Current involvement in another study or trial.
  • Women of child bearing potential or breast-feeding who cannot provide a negative pregnancy test.
  • Known allergy to the components of device, study medication or contrast media that cannot be controlled medically.
  • A medical condition interfering with a dual antiplatelet treatment.
  • Known coagulopathy.
  • Intracranial hemorrhage in the past 30 days apart from the target aneurysm.
  • Ischemic stroke in the past 30 days.
  • Myocardial infarction in the past 30 days.
  • Major surgery in the past 30 days.
  • Evidence of active infection at time of treatment.
  • Co -morbidities or conditions with a life expectancy less than 12 months.
  • Additional Exclusion criteria for ruptured aneurysm at the acute phase:
  • The patient is clinically severely affected (Hunt and Hess grade IV and V).
  • Severe vasospasm is proven during angiography.
  • Proven parenchymal hemorrhage by CT or MRI.
  • Proven subdural hematoma by CT or MRI.

结局指标

主要结局

Effectiveness Aneurysm occlusion (complete or neck remnant)

时间窗: Change from post-procedure to 3-6 and to 7-12 months

Safety Major stroke (ischemic or hemorrhagic) or neurological death related to the treatment of the target aneurysm

时间窗: within 12 months

次要结局

  • Safety Intra-Procedural Complications(at the time of the procedure)
  • Safety Post-Procedural Complications(Change 1day post procedure up to 12months)
  • Effectiveness(at the time of the procedure)

研究者

发起方
Phenox GmbH
申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验